Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI. Chronic hand eczema (CHE) ...

NEW YORK, NY — For immediate control of a hand eczema flare, the old soak and smear approach with moisturizers or corticosteroids might live on, but they are moving to the back of the shelf for ...

Hand eczema, or hand dermatitis, is an inflammatory skin condition. Swollen, itchy, scaly, discolored rashes form on the fingers and hands. The skin may blister and crack, and it can be painful. Hand ...

Epidemiology, clinical presentation. Hyperkeratotic hand dermatitis is more common in men and mainly occurs between the ages of 40 to 60 years old (MennE9, 2000; Warshaw et al., 2003). The skin does ...

Please provide your email address to receive an email when new articles are posted on . In two phase 3 trials, delgocitinib cream improved hand eczema in a greater proportion of patients vs. vehicle.

Chronic hand eczema is common, heterogeneous, and frequently occupational, with high rates of sick leave, job disruption, and notable annual per-patient societal costs in the United States. Diagnostic ...

A deeper understanding of chronic hand eczema (CHE) -- its pathogenesis, clinical subtypes and presentation, and risk factors -- would help expedite quicker diagnosis and appropriate care. That's the ...

Becoming the first approved treatment for chronic hand eczema in the U.S., Leo Pharma A/S’s Anzupgo (delgocitinib) received FDA clearance for an indication that affects 10% of adults worldwide. The ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Lebrikizumab treatment improved both face and hand ...

Treatment options for severe chronic hand eczema are limited and carry troublesome adverse effects. Delgocitinib cream had superior efficacy compared with oral alitretinoin for this patient population ...

Current treatments for chronic hand eczema (CHE) generally fall into two buckets: Either they battle inflammation but lead to unwanted side effects with long-term use or they soothe external symptoms ...

The application is supported by positive data from the pivotal Phase 3 DELTA TEEN trial in the primary and key secondary endpoints.1 If approved, ANZUPGO will be the first treatment option ...